Abstract:
Methods for the treatment or prevention of Gram negative bacterial infection in a vertebrate subject are provided. The methods provide administering an antagonist of bacterial flagellar protein biosynthesis to the vertebrate subject in an amount effective to reduce or eliminate the bacterial infection. Methods for the treatment or prevention of Campylobacter jejuni infection in an avian species or a mammalian species are provided.
Abstract:
New immunological carrier systems, DNA encoding the same, and the use of these systems, are disclosed. The carrier systems include chimeric proteins which comprise a leukotoxin polypeptide fused to a selected antigen. The leukotoxin functions to increase the immunogenicity of the antigen fused thereto.
Abstract:
Novel vaccines for use against Actinobacillus pleuropneumoniae are disclosed. The vaccines contain at least one Actinobacillus pleuropneumoniae outer membrane lipoprotein A, or an immunogenic fragment thereof. Also disclosed are DNA sequences encoding these proteins, vectors including these sequences and host cells transformed with these vectors. The vaccines can be used to treat or prevent porcine respiratory infections.
Abstract:
Novel Haemophilus somnus immunogenic proteins are disclosed. The proteins can be used in vaccine compositions for the prevention and treatment of H. somnus infections. The proteins are conveniently produced using recombinant technology.
Abstract:
Novel vaccines for use against Actinobacillus pleuropneumoniae are disclosed. The vaccines contain at least one A. pleuropneumoniae transferrin binding protein and/or one A. pleuropneumoniae cytolysin and/or one A. pleuropneumoniae APP4. Also disclosed are DNA sequences encoding these proteins, vectors including these sequences and host cells transformed with these vectors. The vaccines can be used to treat or prevent porcine respiratory infections.
Abstract:
The CAMP factor gene of Streptococcus uberis ( S. uberis ) is described, as well as the recombinant production of CAMP factor therefrom. Also disclosed are chimeric CAMP factor constructs, including CAMP factor epitopes from more than one bacterial species. The CAMP factors and chimeras including the same can be used in immunogenic compositions for the prevention and treatment of bacterial infections.
Abstract:
The CAMP factor gen of Streptococcus uberis (S. uberis) is described, as well as the recombinant production of CAMP factor therefrom. CAMP factors can be used in vaccine compositions for the prevention and treatment of bacterial infections.
Abstract:
Vaccines are provided for vaccinating an animal against pathogenic bacteria, including E. coli. The invention also encompasses methods of preparing and methods of use of vaccine strains and compositions that result from or are used in these methods.
Abstract:
New proteins and subunit antigens from P. haemolytica for use in stimulating immunity against respiratory diseases such as pneumonia, including shipping fever pneumonia, are disclosed. The subunit antigens include immunogenic amino acid sequences of P. haemolytica fimbrial protein, P. haemolytica plasmin receptor protein, and P. haemolytica 50 K outer membrane protein and P. haemolytica leukotoxin. The antigens can be used in a vaccine composition, either alone or in combination. Also disclosed are methods of vaccination as well as methods of making the subunit antigens employed in the vaccines.
Abstract:
The bovine lactoferrin (bLF) binding protein of Streptococcus uberis (S. uberis) is described, as well as the gene encoding the bLF (1bp). LF-binding proteins can be used in vaccine compositions for the prevention and treatment of S. uberis infections, particularly mastitis, as well as in diagnostic methods for determining the presence of S. uberis infections. Also disclosed is a regulatory region adjacent to 1bp, termed mga.